**Journal of Gastrointestinal Surgery**  
**Bariatric Surgery Influences beta-Cell Turnover in Non Obese Rats.**  
--Manuscript Draft--

<table>
<thead>
<tr>
<th>Manuscript Number:</th>
<th>JGSU-D-16-01390</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Title:</td>
<td>Bariatric Surgery Influences beta-Cell Turnover in Non Obese Rats.</td>
</tr>
<tr>
<td>Article Type:</td>
<td>Original Article</td>
</tr>
<tr>
<td>Keywords:</td>
<td>Pancreas; Diabetes; Bariatric-surgery; Insulin-Secreting Cells; beta-cell mass</td>
</tr>
</tbody>
</table>
| Corresponding Author: | Jose Arturo Arturo Prada-Oliveira, MD, PhD  
Universidad de Cadiz  
Cadiz, SPAIN |
| Corresponding Author Secondary Information: | |
| Corresponding Author's Institution: | Universidad de Cadiz |
| Corresponding Author's Secondary Institution: | |
| First Author: | Alonso Camacho-Ramírez |
| First Author Secondary Information: | |
| Order of Authors: | Alonso Camacho-Ramírez  
Manuel Blandino-Rosano  
Alfonso Lechuga-Salcho  
Carmen Segundo-Iglesias  
Manuel Aguilar-Diosdado  
Gonzalo Pérez-Arana  
Jose Arturo Arturo Prada-Oliveira, MD, PhD |
| Order of Authors Secondary Information: | |
| Funding Information: | Andalusian Public Health Service  
(Project PI-0170-2010)  
Not applicable |
Bariatric Surgery Influences β-Cell Turnover in Non Obese Rats.

Alonso Camacho-Ramírez PhD²; Manuel Blandino-Rosano PhD³; M. Carmen Segundo-Iglesias PhD¹; Alfonso M. Lechuga-Sanchez PhD³; Manuel Aguilar-Diosdado PhD¹; Gonzalo M. Pérez-Arana PhD¹† and J. Arturo Prada-Oliveira PhD⁵†.

1. Endocrinology and Metabolism Clinical Unit. Puerta del Mar University Hospital. University of Cádiz.
2. Surgery Unit. Puerto Real University Hospital. University of Cádiz.
4. Department of Endocrinology, Diabetes and Metabolism Division. Miller School of Medicine. University of Miami.

† Both authors contributed equally to the work.

Corresponding authors: Dr. JA Prada-Oliveira. Dr. G Pérez-Arana. Department of Human Anatomy and Embryology. Faculty of Medicine. Plaza Fragela s/n. University of Cádiz. Cádiz, 11003. Email: arturo.prada@uca.es. Phone 34956015817. Fax 34956015254.

Grant support: This work was partially supported by the Andalusian Health Service, project PI-O170-2010, related to the CTS-368 Group.

Disclosure: The authors declare no conflict of interest.

Authorship statement: The authors declare that all of them have participated actively in one or more of the steps related with this work, since the intellectual design, the surgical procedures, the laboratory techniques, to the drafting of the manuscript.

Running title: Bariatric surgery and β-cell

Key words: Pancreas; Diabetes; Bariatric-surgery; Insulin-Secreting Cells; beta-cell mass.
ABSTRACT

The aim of this study was to investigate the different bariatric surgeries relationship with pancreatic β-cell turnover. We used healthy adult male Wistar rats to undergo the different techniques. We developed three surgical techniques (malabsorptive, Sleeve gastrectomy and Roux-Y Gastric Bypass-), and two control groups (Sham and fasting control). Pancreatic β-cell mass was measured, as well as apoptosis, proliferation and neogenesis related to cellular turnover. Otherwise, we measured the functional issues to elucidate the physiological role that these surgical techniques trigger in the carbohydrate metabolism (e.g. food intake, weight gain, intraperitoneal glucose tolerance test, and basal glycaemia). Results included the differences that these parameters underwent in each surgical model. The β-cell mass presented modifications that were related with proliferation processes. We reported significant increase of β-cell mass in the malabsorptive technique. Other while the peripheral resistance to insulin trended to reduce in rats underwent with malabsorptive and mixed techniques. The goal of the present study was to present how different bariatric surgical techniques affected on pancreatic β-cell turnover. We considered that these implications of surgery over the endocrine pancreas must be one of the mechanisms related to the improvement of type 2 Diabetes mellitus afterward the bariatric surgery.
INTRODUCTION

The remission of type 2 diabetes (T2DM) has been observed as an additional outcome of surgical treatment for morbid obesity in humans. Induced caloric intake reduction, weight loss and malabsorption of carbohydrates and fats were suggested as explanations for this effect of bariatric surgery on T2DM. More recently, the bile acids, lipoproteins and microbiota have been invoked as effectors in this entero-pancreatic axis. Many mechanisms have been proposed but the mechanism of this success remain unclear.

The glycaemic control often occurs prior to significant weight loss in surgical patients, and even glycaemic homeostasis are independent of the nonsurgical procedures (as gastric band). Nowadays, it is assumed that glycaemic control might be a direct effect on insulin secretion or sensitivity.

We inferred about the idea that insulin secretion must be related to cellular changes in endocrine pancreas. Pancreatic β-cells adapt to stress situation, including obesity, pregnancy and surgery. We believe that improvement of bariatric surgery must be related to changes in cellularity of β-cell mass, which it is at the basis of changes in insulin secretion. There must be some effectors acting as stimuli for these endocrine changes of the pancreas. Probably many substances have been implied in this enteral-axis, which finally will be the executers on β-cell proliferation.

Several incretins have been signed in this mechanism of stimuli over the pancreatic cellularity. GLP-1 or PYY -both secreted by the L-cell in the ileum- or ghrelin in the antrum of the stomach; all of which have been involved in physiological and physio-pathological changes in the entero-insular axis and β-cell mass. But not exclusively, since different peptides –GIP, leptin or CCK are among those- are already object of studies in this sense.
However, the study of the relative degree of beta-cell mass changes related to the portions and extension of digestive tube implied has not been reported. In this way, many studies reported that enhanced delivery of nutrients to the distal intestine and increased secretion of hindgut signals might affect the entero-insular axis. These explanations could be related to the pathophysiological consequences of some techniques (e.g. Roux–Y Gastric bypass, RYGB), which exercise a massive distortion of the digestion and absorption processes. However, this hypothesis does not explain the positive behaviour of restrictive techniques (as Sleeve Gastrectomy, SG), which is receiving progressively more attention in the clinic and is broadly employed.

Therefore, we hypothesised that the digestive tube must trigger on the cellularity of the endocrine pancreas. All the entero-hormones, which have been related with a complex stability of homeostasis named as incretin-anti-incretin balance, are involved in the reported glycaemic improvement of the T2DM, by the way of increased β–cell turnover.

This β-cell mass is severely affected in the long-term obesity and T2DM. Many reports showed that β-cell function is clearly improved after bariatric surgery. Around this, the purpose of the present study was to know how different bariatric procedures could affect pancreatic β-cell mass homeostasis. We employed a healthy, non-obese, animal model, the Wistar rat, in order to reduce the interferences with concomitant pathologies.

We included a malabsorptive model by resecting 50% of the small bowel to the usual bariatric techniques related to human treatment (RYGB and SG). Thus, IR50 is considered as a purely malabsorptive surgical technique. Even though this technique was actually rejected as a bariatric surgery, it is included here to complete the sequence of variation related to these surgical models.
Bariatric surgery and $\beta$-cell

We measured various functional issues to elucidate the carbohydrate metabolism for each surgical group. These physiological parameters were triggered as consequences to the surgical techniques. We completed a sequence of morphometric parameters to conclude the trend of the $\beta$-cell, which included the measurements of pancreatic $\beta$-cell mass, apoptosis, proliferation and neogenesis. We hypothesised that the $\beta$-cell mass must be modified after bariatric surgery, and this $\beta$-cell mass modification could partially be in the basis of the T2DM clinical amelioration.

MATERIAL AND METHODS

Animals
All animal procedures were performed with the approval of the University of Cadiz Committee for the Ethical Use and Care of Experimental Animals. The 30 male Wistar rats were stabled in randomized groups under constant temperature and humidity conditions in a 12-hour light/dark cycle, with *ad libitum* access to normal chow and water. We did not used female rats was to avoid the cyclic variations of gonadotropin hormonal effect on the glycaemic metabolism.

Weight gain and feed intake. Basal glycaemia.
To evaluate the effect of bariatric surgery in animals, we controlled the weight increase of the animals, as well as the grams of feed that these animals ingested. The chow intake was quantified every two days for the first month after surgery. The weight increase was measured every two days for the first month after surgery, and every week for the last two months.
Once a week, the basal glycaemia was measured with a glucometer (Glucocard G-Meter 1810, Menarini diagnostics, Italy) and expressed as mg of glucose/decilitre of blood.

**Surgical interventions and fasting controls**

The fasting control group (FC) was subjected the same preoperative and postoperative conditions as the operated groups, with a 12 hour-fasting pre- and post-surgical period. All surgical procedures were performed in anesthetised animals with continuous infusion of Isofluorane 3% V/V (Isoflo, Abbott 571329.8). An intake re-adaptation period followed each surgery to normalize fasting.

IR50 as the malabsorptive bariatric surgery was performed in the following steps. A laparotomy of about 3 cm in the midline of the abdomen. We identified the angle of Treitz and the ileocecal valve as anatomical references. The bowel between these points was exposed and measured. We made a resection of the central 50%, followed by an end-to-end anastomosis with 5-0 monoplane silk suture (polypropylene, Ethicon Prolene), leaving the proximal half of the jejunum and the distal half of the digestive tube. So, we did not remove the ileum. The ileum in the rat is shortened than in human. This procedure did not affect the ileum. Lastly, instillation of physiological saline at 37°C in abdominal cavity and closure of the abdominal wall in one layer was done. These final steps were repeated in every surgical procedure.

The RYGB, mixed -malabsorptive and restrictive- bariatric surgery, involved the exclusion of the proximal intestine by the bypass of the duodenum and a part of the jejunum, as well as the reduction of stomach to the fore-stomach. The stomach was exposed and we sectioned the gastric fundus, while preserving approximately 20% of the original gastric volume. The jejunum was dissected at 8 cm from the ligament of Treitz, and the terminal jejunum of the section was connected via end-to-end anastomosis to the preserved for fundus. The antro-
jejunal loop (biliopancreatic loop) was continued with the alimentary loop at 10 cm of the fundus-jejunum anastomosis.

Sleeve Gastrectomy (SG) was performed by a laparotomy of 5 cm in the upper third of the abdomen through sectioning of the gasto-splenic ligament and exposing the stomach. A curved forceps was applied from the angle of Hiss to antrum, performing a cylindrical stomach of approximately 0.5 cm of diameter. The stomach section delimited the section of the most fundus, stomach-corpus at greater curvature level, and antrum; the pylorus was preserved. The SG reduced the initial stomach volume by approximately 20%. SG reproduced the actual selective technique used in humans as the restrictive model of bariatric surgery.

The Sham-technique (Sham) reproduced the surgical aggression over the digestive tract and the stress of both pre-surgery and post-surgery, but maintains the integrity of the digestive tube. Sham was performed by an incision of about 3 cm in the middle area of the abdomen, exposing the small bowel loops. After we measured the size from the angle of Treitz to ileocecal valve, a transversal enterotomy section was performed, without intestinal resection, and end-to-end anastomosis.

**Intra-peritoneal glucose tolerance test (IPGTT):**

A blood sample of 0.5 ml was collected from the tail vein of each fasted animal. Then, an intraperitoneal injection of 40% solution of glucose was administered (2 gr/Kg body weight) followed by blood sampling from the tail vein at 15, 30, 60 and 120 minutes following glucose administration. We realized the IPGTT monthly. Basal glycaemia was measured pre-operatory and weekly after surgery. Glycaemia was measured with a glucometer (Glucocard G-Meter 1810, Menarini diagnostics, Italy) and expressed as mg of glucose/decilitre of blood.

**β-cell mass quantification:**
Three months after surgical intervention, animals were sacrificed by an intraperitoneal Chloral Hydrate overdose and perfused with Bouin’s solution (25% Formalin/75% H₂O saturated with Picric acid). After this, the pancreas was resected, weighed (precision scale Ohaus Pioneer Mod PA 3102), and post-fixed in Bouin’s solution, 24h at 4ºC. The fixed pancreas was dehydrated, paraffin embedded and longitudinal 10 μm microtome sections were obtained. To calculate β-cell mass, insulin producing cells were stained using a monoclonal mouse anti-insulin antibody (Sigma-Aldrich, I-2018 USA), and a secondary peroxidase conjugated goat anti-mouse IgG antibody (Sigma, Mouse Extra-2); then revealed with solution of 0.3 mg/ml of 3,3’Diaminobenzidine (Sigma, D5905) in presence of 0.2 µl/ml of H₂O₂ under microscopic control, counterstained with Harris´s haematoxylin.

The insulin-positive areas were measured using a microscope equipped with a digital camera and the image analysis Image J. Those who performed the measurements were not aware of which experimental group the samples belonged. β-Cell mass was measured as an insulin-positive area/total pancreatic area ratio by the total pancreas weight, and it was expressed in mg.

**Apoptosis Assays:**

To determine β-cell apoptosis, 10 μm tissue sections from the pancreas were mounted on microscope slides and rehydrated through graded ethanol to PBS. The Dead End Fluorometric Terminal Deoxinucleotidil-Transferase-mediated 2´-deoxyuridine 5´-Triphosphate nick end Labelling (TUNEL) system (Promega, USA) were used according to the manufacturer instructions. Insulin was simultaneously counterstained using polyclonal mouse anti-insulin antibody (Sigma-Aldrich, USA) incubated overnight at 4ºC; and then stained with a secondary anti-mouse IgG antibody (Alexa 546) conjugated (Molecular Probes Inc. Eugene, USA). To determine the apoptotic fraction, TUNEL+/Insulin+ cells and islet areas were quantified by 20
Bariatric surgery and β-cell

islets/per sample. We used an image analysis Cell D software (Olympus, Hamburg, Germany). Results were noted under randomized conditions by a single investigator and expressed as the number of TUNEL+/insulin+ cells/mm² of islet.

**Proliferation Assays:**

Proliferation was assessed by double immunostaining, using polyclonal rabbit anti-Ki67 (Ab-Cam, AB16667, UK) and monoclonal mouse anti-insulin (Sigma-Aldrich, I-2018 USA) antibodies, according to the manufacturer instructions. Previously, sections from the pancreas were incubated for 30 min with 0.1% Triton x-100 in PBS for tissue permeabilization, washed with PBS, and then incubated for 30 min with 4% BSA blocking solution in PBS at room temperature. Sections were stained using anti-rabbit IgG Alexa 488 and anti-mouse IgG Alexa 546 conjugated antibodies (Molecular Probes Inc Eugene, USA). The proliferation ratio was quantified in 40 islets/per sample. The results were expressed as the number of Ki67+/Insulin+ cells/mm² per area of pancreatic islets. We used the image analysis Cell D software (Olympus, Hamburg, Germany).

**Neogenesis study:**

To study PDX-1 expression, as neogenesis marker, the pancreas sections were obtained as described above from rats at 3 months-old after surgical intervention. We retrieved sections for 10 min with heat in citrate buffer pH 6.7 solution, stained with monoclonal rabbit anti-PDX-1 antibody (Ab-Cam, 47267 UK) and labelled using biotin conjugated anti-rabbit IgG antibody (Sigma-Aldrich, B8895, USA) and revealed with a solution of 0.3 mg/ml of 3,3′Diaminobenzine (Sigma, D5905) under microscopic control and counterstained with Harris’s haematoxylin. The results were observed qualitatively in 12 pancreas areas/per animal group.

**Statistical Analysis**
Bariatric surgery and β-cell

Measurement data were expressed as mean±SEM. The data were analysed with the Mann Whitney-U test, and \( p<0.05 \) was considered statistically significant. All statistical analyses were performed using SPSS statistical software.
RESULTS

Weight measurement and food intake

Body weight gain in rats was monitored from surgery to the time of sacrifice as described in methods. No differences appeared between RYGB, Sham and FC (FIG 1A). But there are differences between IR50 group and the Sham and FC groups ($p<0.05$) from the tenth week after surgical to sacrifice (Fig 1B). There are also significant differences between the SG group and the Sham and FC groups ($p<0.01$) from surgery to time of sacrifice. In the case of food intake, the graphs showed a lower intake in the SG group in relation to Sham and FC groups ($p<0.05$) (Fig 1F) but not in RYBG or IR50 groups (Fig 1D and Fig 1E).

Otherwise, no changes were observed in the basal glycaemia during the period of the study. These data had no significant differences between groups.

Intra-peritoneal glucose tolerance test (IPGTT)

An intra-peritoneal glucose tolerance test (IPGTT) was performed in each group every four weeks from surgery to sacrifice. No differences appeared between the geometries of the curves along the study in RYGB and SG groups (Fig 2A and Fig 2E) versus the control groups. But there were significant differences among the curves for the first month, for the second ($p<0.01$) month and third ($p<0.05$) month in IR50 group (Fig 2C).

We did not find any difference in the area under the curve (AUC) between the SG and Sham and FC groups during the study (Fig 2F). However, in the RYGB group there were important differences ($p<0.01$) in AUC values (+ 15 mg dL/min) respect to the FC group AUC values (+10 mg dL min$^{-1}$) at eight weeks (Fig 2B). Differences were also found among the FC group and IR50 group AUC values for the second month (+15 mg dLmin$^{-1}$ versus +19 mg dL/min) ($p<0.05$) (Fig 2D). Finally, differences also persisted in the third month between the IR50 group AUC
values (+15 mg dL min\(^{-1}\)) and the FC group AUC values (10 mg dL min\(^{-1}\)) \(p<0.01\); but also between the IR50 group AUC values and the Sham (10 mg dL/min) \(p<0.05\) (Fig 2D).

**\(\beta\) cell mass**

Pancreatic \(\beta\)-cell mass quantification was accomplished for each group immediately after sacrifice. Three months following surgery, no \(\beta\)–cell mass significant differences appeared among the RYGB or SG groups versus the Sham and FC groups (Fig 3). On the other hand, there were significant differences among the FC and the Sham control \(p<0.05\) \(\beta\)–cell mass values (+5 mg and +6 mg, respectively) versus the IR50 group \(\beta\)–cell mass value (Fig 3).

**Proliferation assays**

The \(\beta\)–cell proliferation was analysed through the presence of the Ki67 proliferation marker in the \(\beta\)–cell nucleus. The data showed high rates of replication in the IR50 (showed +9 Ki67 positive cells/mm\(^2\) insulin positive area), and the RYGB (presented +11 Ki67 positive cells/mm\(^2\) insulin positive area) over control groups \(p<0.05\) (Fig 4). The SG group proliferation rates were decreased (+5 Ki67 positive cells/mm\(^2\) insulin positive area) when compared to the Sham and FC group (+8 and +7 Ki67 positive \(\beta\)-cells/mm\(^2\) insulin positive area, respectively) \(p<0.05\) (Fig 4).

**Apoptosis Assay**

Rate of \(\beta\)–cell apoptosis was performed using the TUNEL system in each group. No significant differences appeared among any of the surgical groups versus Sham or FC groups.

**PDX-1 Analysis**

Presence of new \(\beta\)–cells from non \(\beta\)–cells, known as differentiation, was assessed using PDX-1 transcription factor immunostaining in pancreas samples for each group. The study showed that any group expressed variations in the immunostained expression of PDX-1 (Figs 6A and
Bariatric surgery and β-cell

6B) except in the RYGB group, where visually greater intensity and frequency immunostaining appeared as we can see in Fig 6C.
DISCUSSION

The endocrine pancreas has a significant remodelling capacity, attending not only to several physiological conditions, but also to pathological status such as obesity. Even, this mechanism prevents the development of T2DM in many patients. The changes in β-cell number and size, islet neogenesis, proliferation and apoptosis contribute to the remodelling of the endocrine pancreas. The balance among these cellular mechanisms determine the change in β-cell mass. Therefore, the study of β-cell mass dynamic plays an important role in the adaptation to obesity, as well as in the pathogenesis of T2DM. Many studies had focused on bariatric surgery effect on pathologic models of T2DM and obesity. Rather than following this model, our experiments were designed to analyse the effect of bariatric surgery on glucose control and β-cell population behaviour in a non-obese and non-diabetic model. We promoted an altered transit of aliment across the digestive tube. The pancreas were not affected at the beginning of the study, and β-cell islets were able to accommodate to the special situation generated for the bariatric surgery. Then, the changes in the islets were observed on the basis of a healthy pancreas.

It is well known the hyperglycaemia toxic effect on glucose-sensing of β-cell, as occur in obesity and T2DM, that lately potentiate β-cell dysfunction. So, we considered that the histological consequences observed and described in this paper could be diminished because these pancreases were able to stabilise the glucose homeostasis. These pancreas of healthy rats were not previously damaged for the mentioned factors, without the demand of workload on the β-cell population. The glycemic parameters showed a resultant equilibrium, which represented the histological changes reported in this paper.
To the best of our knowledge, not many previous studies have focused on the changes in pancreas islets related to surgical models, in order to valuate parameters about the β-cell mass and the cellular turnover. We report how these processes could be related to the maintenance of glucose homeostasis.

Firstly, the results related to the weight gaining and food intake showed that surgical processes reproduced those applied in the human clinic. The functional parameters were according to the expected alteration of digestive tube and the increased transit and absorption of nutrients. The animals of surgical groups tolerated the surgery; all surgical groups gained less weight and food intake was reduced in models that affected the stomach. On the other hand, the basal glycaemias were not altered in all of the studied groups. So, we consider that the altered flow of feed, or the swift absorption of nutrients were not enough stimuli to unbalance the homeostasis. These must be related to the condition of the healthy animals, with healthy endocrine pancreases, which were able to adapt to the surgical conditions.

In our study, the different surgeries had various consequences on glucose tolerance. Through the study of the IPTTG test, the results showed significant differences between FC group versus IR50 and RYGB groups in some intervals of the study (Fig 2). One common point in the IR50 and RYGB surgical groups was that both groups produced a shortening of food transit in the small intestine (specifically by the jejunum), unlike in the SG group. These new anatomical situations, according to our data, seemed to cause a modification in their AUC. This effect could probably be due to the early arrival of food to the ileum. It is well known that the rapid influx of nutrients may trigger the release of several incretins (as GLP-1, GIP, Oxyntomodulin, PYY, etc.) and this would lead to a normalization of the AUC in both groups. 11, 16, 31. In this
Bariatric surgery and \( \beta \)-cell

sense, the AUC is marking the global capacity of the endocrine pancreas to resolve the glucose overload.

In addition, we could see a normalization of the AUC in the RYGB group from the eighth week. However, this normalization of the AUC did not occur in the IR50 group. This different behaviour in the IR50 group could be explained by the decreased transit of food through the duodenum, which results in less secretion of GIP by K-cells \(^3\), \(^32\). This idea was the etiological basis of the foregut hypothesis. It argued that RYGB, and partially RI50, bypasses the foregut, so it was inhibited the \( \beta \)-cell function, influenced by the GIP, originating from the duodenum and proximal jejunum \(^2^2\). These results could reinforce the role of the ileum.

We explored the effect of these bariatric surgeries on the pancreas because we considered that islets must be the target of the entero-insular axis. We believe that the improved of \( \beta \)-cell dysfunction must be related to changes in the cellularity of islets, and this could be a consequence of the surgically altered anatomy of the gastrointestinal system.

Even, some authors had reported that the surgery per se cause an inflammatory distress, which impair insulin sensitivity. This metabolic stress related to surgery could explain why our Sham control presented different parameters than FC. We reported results which Sham group presented significant differences with surgical groups, meanwhile did not occurred with FC \(^3^3\). First, we showed that \( \beta \)-cell mass was slightly increased in the surgical groups following surgery, but only the IR50 group presented with significant differences versus the FC and the Sham groups (Fig 3B). These effects could be explained by increased stimulation of the ileum due to earlier presence of food, which could lead to an elevated release of GLP-1 or PYY \(^1^1\), \(^1^8\), \(^3^1\). This idea could be supported for the data of RYGB group. The behaviour of the AUC and the light increase of \( \beta \)-cell mass in the RYGB group indicated a common aspect with RI50. Both groups, RYGB and RI50 (malabsorptive and mixed surgical groups) incited an early arrival of
Bariatric surgery and β-cell

nutrients to the ileum. However, this mechanism was occurred sooner in the IR50 when compared to the RYGB group, so the effect was greater and earlier in the IR50 group. Both groups, IR50 and RYGB, had significant proliferation rates respect to the controls groups (Fig 4), which correlate with β-cell mass changes.

The possible role of GLP-1 is controversial. The proliferative effect of the release of GLP-1 on β-cell population had well described 34, 35, 36, 37. But some authors considered that GLP-1 has not a direct effect on the pancreas, and it is related to satiety by acting at central nervous system 38. Otherwise, the GLP-1 receptor modifications have been excluded as related to the T2DM improvement after SG 39.

The SG group showed a significant low proliferation ratio respect to the controls (Fig 4), but did not show a decreased β-cell mass respect to the controls (Fig 3). The explanation of this could be a slight decrease in the β-cell apoptosis ratio in SG group. However, no significant differences in the β-cell apoptosis rates appeared between any studied groups (Fig 5). Thus, the explanation for this effect must be an increased phenomenon of cell differentiation from stem cell to β-cell 40. This fact was supported by the normal presence of PDX-1 stained β-cells, as observed in SG samples (Figure 6).

Regarding the PDX-1 study parameters, the cell differentiation from stem cell to β-cell 40, 41 after bariatric surgery, showed more data in the other surgical groups. In the RYGB samples, we observed an increased presence of PDX-1 β-cell (Figure 6C). The increased β-cell differentiation is related to some stimulating factors (e.g. GLP-1 or PYY) on the pancreas 18, 19, 20.

We note that both surgical techniques (RYBG and RI50) have a common region, which is affected –the duodenum and first jejunal portion–, and this increment could be related to a direct influence to the pancreas. But, in a contrary sense, the exclusion of duodenum to the
Bariatric surgery and β-cell

nutrients in the RYGB versus the RI50 could explain the different effect of both techniques on the pancreas. We think that the so called anti-incretin effect, secreted in the duodenum (e. g. CCK or GIP) could be in the basis of this differences 16, 21, 22.

The complete observation of data leads us to suggest the presence of two possible mechanisms that could be in the basis of the β-cell mass increase. The first proposed mechanism is the direct path due to the early presence of food in ileum, as is the case of the IR50 and RYGB surgeries. The premature appearance of partially digested nutrients in the ileum seemed to show an earlier increase in proliferation. The proliferation mechanism could be related to ghrelin level changes 14, 42. This direct pathway could too act on β–cell mass through a release of GLP-1, a recognized stimulatory of β-cell proliferation agent secreted by L-cells 4, 10, 34, 35. We consider that the entero-hormonal axis must be the effector of the final changes in the cellular conformation of endocrine pancreas.

A second path could be related to the restriction of the transit of food through the jejunum. The mechanism appeared too in the IR50 and RYGB surgical groups. This second mechanism would act indirectly through a transient modification of glucose tolerance. The surgical processes that induce a reduction of glucose tolerance could stimulate an increase in β-cell mass, due to the high blood glucose level 43, 44. But in the case of the IR50 group, this mechanism seems to be more important than in the RYGB group (Fig 2). This is related to the fact that the IR50 samples experienced a shorter transit through the jejunum than in the RYGB group. Therefore, the second proposed mechanism would reinforce the first path we described above, the enhanced growth of β-cell mass.
REFERENCES


Bariatric surgery and β-cell


Bariatric surgery and β-cell


FIGURE LEGENDS

Figure 1. Weight gain in groups RYGB (Fig 1A), IR50 (Fig 1B) and SG (Fig 1C) from surgery to sacrifice. Significant differences were found between IR50 group (p<0.05) and SG group (p<0.01) versus Sham and FC groups. Food intake in RYGB (Fig 1D), IR50 (Fig 1E) and SG (Fig 1F) versus control groups, for the first month after surgery. No food intake difference in IR50 and RYGB were reported (Fig 1D and Fig 1E). Significant difference (p<0.05) between food intake values for SG group and FC group were seen. The Y-axis in weight gain of IR50 (Fig 1E) had a different unit in order to facilitate the depiction.

Figure 2. IPTTTG geometry curves development in surgery groups at the first, second and third months (Fig 2A, Fig 2C and Fig 2E) and area under curve (AUC) in surgical, sham and fasting control groups, expressed as mg/dL/min⁻¹ (Fig 2B, Fig 2D and Fig 2F). Important differences appeared in IPTTTG curves in the IR50 group between first and the second months (p<0.01) and
first and the third months ($p<0.05$) (Fig 2C). Also, significant differences were seen in the AUC at the second month between the IR50 surgery and fasting control group ($p<0.05$) and between the IR50 surgery and sham group ($p<0.05$) and the IR50 surgery and fasting control group at the third month ($p<0.01$) (Fig 2D). There were no differences in IPTTG curve development in RYGB and SG groups (Fig 2A and Fig 2E). However, significant differences were seen in the AUC between the RYGB and fasting control groups at the second month ($p<0.05$) (Fig2B). The Y-axis in the IPTTG and the AUC of SG (Fig 2E and 2F) had a different unit in order to facilitate the depiction.

**Figure 3.** β-cell mass quantification expressed as mg. The difference appeared in this study between Sham control group and IR50 group, with the IR50 group β-cell mass having roughly 0.6 times more β-cell mass ($p<0.05$) compared to the Sham control group.

**Figure 4.** Proliferation assays. Rates of β-cell proliferation expressed as the number of β–cells, which expressed Ki67 positive/insulin positive area (mm$^2$). IR50 and RYGB groups show higher proliferation rates than Sham control group ($p<0.05$). However, the rate of β-cell proliferation appeared diminished in SG group, compared to Sham control ($p<0.05$).

**Figure 5.** Apoptosis assays. Rates of β-cell apoptosis expressed as the number of TUNEL positive β-cells/insulin positive area (mm$^2$) for all of the groups. No one group showed differences in β-cell apoptosis ratio between surgical groups and controls.

**Figure 6.** Images showing pancreas expression of PDX-1. Fasting control group (6A), Sham control group (6B) and RYGB group (6C). Enhanced expression of PDX-1 appeared in the RYGB group compared to the other groups.
Figure 3: Bar graph showing beta cell mass (mg) for different groups: CA, SHAM, RYGB, RI50, and SG.

- CA: 15 ± 2 mg
- SHAM: 10 ± 1 mg
- RYGB: 22 ± 3 mg
- RI50: 25 ± 2 mg
- SG: 17 ± 1 mg

Significance indicated by an asterisk (*) suggests a statistically significant difference between RYGB and the other groups.
Figure

Graph showing Ki67+ β-cells/insulin + area for different groups: CA, SHAM, RYBG, RIS0, and SG. The graph indicates statistical significance with asterisks above the bars.
Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting  http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit  http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.